Therapeutic potential of fecal microbiota transplantation in colorectal cancer based on gut microbiota regulation: from pathogenesis to efficacy DOI Creative Commons

Chen Gu,

Gengyu Sha, Baoqing Zeng

et al.

Therapeutic Advances in Gastroenterology, Journal Year: 2025, Volume and Issue: 18

Published: Jan. 1, 2025

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide, with its progression intricately linked to gut microbiota dysbiosis. Disruptions in microbial homeostasis contribute tumor initiation, immune suppression, and inflammation, establishing the as key therapeutic target. Fecal transplantation (FMT) has emerged transformative approach restore balance, enhance responses, reshape microenvironment. This review explores mechanisms underlying FMT’s potential, evaluates advantages over other microbiota-based interventions, addresses challenges such donor selection, safety concerns, treatment standardization. Looking forward, integration FMT into personalized CRC therapies requires robust clinical trials identification predictive biomarkers optimize efficacy safety.

Language: Английский

Therapeutic potential of fecal microbiota transplantation in colorectal cancer based on gut microbiota regulation: from pathogenesis to efficacy DOI Creative Commons

Chen Gu,

Gengyu Sha, Baoqing Zeng

et al.

Therapeutic Advances in Gastroenterology, Journal Year: 2025, Volume and Issue: 18

Published: Jan. 1, 2025

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide, with its progression intricately linked to gut microbiota dysbiosis. Disruptions in microbial homeostasis contribute tumor initiation, immune suppression, and inflammation, establishing the as key therapeutic target. Fecal transplantation (FMT) has emerged transformative approach restore balance, enhance responses, reshape microenvironment. This review explores mechanisms underlying FMT’s potential, evaluates advantages over other microbiota-based interventions, addresses challenges such donor selection, safety concerns, treatment standardization. Looking forward, integration FMT into personalized CRC therapies requires robust clinical trials identification predictive biomarkers optimize efficacy safety.

Language: Английский

Citations

0